Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kissling, E, Hooiveld, M, Sandonis Martín, V, Martínez-Baz, I, William, N, Vilcu, A-M, Mazagatos, C, Domegan, L, de Lusignan, S, Meijer, A, Machado, A, Brytting, M, Casado, I, Murray, J-LK, Belhillil, S, Larrauri, A, O'Donnell, J, Tsang, R, de Lange, M, Rodrigues, AP, Riess, M, Castilla, J, Hamilton, M, Falchi, A, Pozo, F, Dunford, L, Cogdale, J, Jansen, T, Guiomar, R, Enkirch, T, Burgui, C, Sigerson, D, Blanchon, T, Martínez Ochoa, EM, Connell, J, Ellis, J, van Gageldonk-Lafeber, R, Kislaya, I, Rose, AM, Valenciano, M
Otros Autores: I-MOVE-COVID-19 primary care study team
Formato: Journal article
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control 2021
Descripción
Sumario:We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.